Dmitry Yaranov, MD
Advanced Heart Failure and Transplant Cardiology · Memphis, TNNPI 1255607164
Payments from drug & device makers
Across 1,312 payments — averaging $868.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$354K
- Cvrx, Inc.$134K
- Boehringer Ingelheim$122K
- Abbott$111K
- Merck$86K
- Bridgebio Pharma, Inc.$80K
- plus $252K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 236 | $354,113 |
| Cvrx, Inc. | 197 | $133,757 |
| Boehringer Ingelheim | 94 | $122,190 |
| Abbott | 342 | $111,465 |
| Merck | 101 | $85,755 |
| Bridgebio Pharma, Inc. | 50 | $79,948 |
| Alnylam Pharmaceuticals Inc. | 79 | $74,925 |
| Daxor Corporation | 24 | $50,292 |
| Lilly USA, LLC | 34 | $40,200 |
| Astrazeneca UK Limited | 2 | $37,671 |
| Akcea Therapeutics, Inc. | 34 | $25,115 |
| Briohealth Solutions, Inc. | 2 | $14,333 |
| Nuwellis, Inc. | 6 | $6,343 |
| Medtronic(2 entities) | 11 | $1,018 |
| Pfizer | 21 | $433 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $398 |
| Actelion Pharmaceuticals US, Inc. | 19 | $350 |
| Novartis | 17 | $309 |
| Abiomed | 4 | $237 |
| E.r. Squibb & Sons, L.L.C. | 4 | $182 |
| Atricure, Inc. | 2 | $158 |
| Bayer | 8 | $136 |
| Boston Scientific | 3 | $116 |
| Daiichi Sankyo Inc. | 3 | $69 |
| United Therapeutics Corporation | 3 | $61 |
| Lexicon Pharmaceuticals, Inc. | 2 | $36 |
| Edwards Lifesciences | 1 | $32 |
| Johnson & Johnson | 2 | $28 |
| Novo Nordisk | 1 | $24 |
| Endotronix, Inc. | 1 | $18 |
| Amgen | 1 | $14 |
How this compares
$1,139,726 in reported general payments places this provider in the 95th percentile of 28 advanced heart failure and transplant cardiology providers in Tennessee.
See all advanced heart failure and transplant cardiology providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other advanced heart failure and transplant cardiology in Memphis
- John JefferiesMemphis$1.4M
- Jeffrey TowbinMemphis$312K
- Kaitlin RyanMemphis$31K
- Elyse MillerMemphis$2K
- Osama MahmoudMemphis$1K
- Nobuyuki IkedaMemphis$373
- Lynne StevensonNashville$720K
- Mark AaronNashville$146K
- Jonathan MenachemNashville$79K
- Richa GuptaNashville$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.